Avecia sells Pharmaceuticals business unit to Nicholas Piramal India Ltd
The sale includes all Avecia Pharmaceuticals' assets and operations at its principal UK site in Huddersfield, England, a large scale fermentation asset at Billingham, England, a High Potency Substance (HPS) facility at Grangemouth in Scotland and its North American operation - Torcan Chemicals in Aurora, Canada. All 350 Avecia Pharmaceuticals' employees are included in the transaction.
David Killworth, Vice President Avecia Pharmaceuticals said: "I am delighted that we will be joining forces with Nicholas Piramal India Ltd to create a major new force in the custom synthesis business. This transaction brings together the strengths of Indian and Western operations to provide a total lifecycle solution which addresses the changing requirements of the global pharmaceutical and biotechnology sectors".
Most read news
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.